Metsera Declares Novo Nordisk Proposal as Superior Company Proposal

Summary

On October 29, 2025, Metsera, Inc.'s Board of Directors declared an unsolicited proposal from Novo Nordisk A/S as a 'Superior Company Proposal' under its Merger Agreement with Pfizer Inc. The Novo Nordisk Proposal values Metsera at up to $77.75 per share, a total of approximately $9.1 billion. This triggers a negotiation period for Pfizer to adjust the terms of the Pfizer Merger Agreement. Metsera shareholders do not need to take any action at this time. The Pfizer Merger Agreement remains in effect.